Meral Beksac

42PUBLICATIONS
276CO-AUTHORS
NanomedicineGenetic immunologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biochemistry - proteins and peptides (incl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Jun 03, 2026
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.

|May 27, 2026
Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes.

|May 12, 2026
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

|Mar 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar, Sundar Jagannath, Katja C Weisel

|Feb 25, 2026
[<sup>11</sup>C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma.

Elgin Ozkan, Burak Demir, Guldane Cengiz Seval

|Jan 12, 2026
Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.

Meral Beksac, Tulin Fıratlı Tuglular, Francesca Gay

Pageof 7

Frequent Collaborators

8 joint publications

Güldane Cengiz Seval

6 joint publications

Maria-Victoria Mateos

6 joint publications

Stefan Schönland

6 joint publications

Patrick J Hayden